DOCSLIB.ORG

GCC2 (NM 181453) Human Tagged ORF Clone Product Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GCC2 (NM 181453) Human Tagged ORF Clone Product Data OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RG219795 GCC2 (NM_181453) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: GCC2 (NM_181453) Human Tagged ORF Clone Tag: TurboGFP Symbol: GCC2 Synonyms: GCC185; RANBP2L4; REN53 Vector: pCMV6-AC-GFP (PS100010) E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RG219795 representing NM_181453 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGAGGATCTTGTTCAAGATGGGGTGGCTTCACCAGCTACCCCTGGGACCGGGAAATCTAAGCTGGAAA CATTGCCCAAAGAAGACCTCATCAAGTTTGCCAAGAAACAGATGATGCTAATACAGAAAGCTAAATCAAG GTGTACAGAATTGGAGAAAGAAATTGAAGAACTCAGATCAAAACCTGTTACTGAAGGAACTGGTGATATT ATTAAGGCATTAACTGAACGTCTGGATGCTCTTCTTCTGGAAAAAGCAGAGACTGAGCAACAGTGTCTTT CTCTGAAAAAGGAAAATATAAAAATGAAGCAAGAGGTTGAGGATTCTGTAACAAAGATGGGAGATGCACA TAAGGAGTTGGAACAATCACATATAAACTATGTGAAAGAAATTGAAAATTTGAAAAATGAGTTGATGGCA GTACGTTCCAAATACAGTGAAGACAAAGCTAACTTACAAAAGCAGCTGGAAGAAGCAATGAATACGCAAT TAGAACTTTCAGAACAACTTAAATTTCAGAACAACTCTGAAGATAATGTTAAAAAACTACAAGAAGAGAT TGAGAAAATTAGGCCAGGCTTTGAGGAGCAAATTTTATATCTGCAAAAGCAATTAGACGCTACCACTGAT GAAAAGAAGGAAACAGTTACTCAACTCCAAAATATCATTGAGGCTAATTCTCAGCATTACCAAAAAAATA TTAATAGTTTGCAGGAAGAGCTTTTACAGTTGAAAGCTATACACCAAGAAGAGGTGAAAGAGTTGATGTG CCAGATTGAAGCATCAGCTAAGGAACATGAAGCAGAGATAAATAAGTTGAACGAGCTAAAAGAGAACTTA GTAAAACAATGTGAGGCAAGTGAAAAGAACATCCAGAAGAAATATGAATGTGAGTTAGAAAATTTAAGGA AAGCCACCTCAAATGCAAACCAAGACAATCAGATATGTTCTATTCTCTTGCAAGAAAATACATTTGTAGA ACAAGTAGTAAATGAAAAAGTCAAACACTTAGAAGATACCTTAAAAGAACTTGAATCTCAACACAGTATC TTAAAAGATGAGGTAACTTATATGAATAATCTTAAGTTAAAACTTGAAATGGATGCTCAACATATAAAGG ATGAGTTTTTTCATGAACGGGAAGACTTAGAGTTTAAAATTAATGAATTATTACTAGCTAAAGAAGAACA GGGCTGTGTAATTGAAAAATTAAAATCTGAGCTAGCAGGTTTAAATAAACAGTTTTGCTATACTGTAGAA CAGCATAACAGAGAAGTACAGAGTCTTAAGGAACAACATCAAAAAGAAATATCAGAACTAAATGAGACAT TTTTGTCAGATTCAGAAAAAGAAAAATTAACATTAATGTTTGAAATACAGGGTCTTAAGGAACAGTGTGA AAACCTACAGCAAGAAAAGCAAGAAGCAATTTTAAATTATGAGAGTTTACGAGAGATTATGGAAATTTTA CAAACAGAACTGGGGGAATCTGCTGGAAAAATAAGTCAAGAGTTCGAATCAATGAAGCAACAGCAAGCAT This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 GCC2 (NM_181453) Human Tagged ORF Clone – RG219795 CTGATGTTCATGAACTGCAGCAGAAGCTCAGAACTGCTTTTACTGAAAAAGATGCCCTTCTCGAAACTGT GAATCGCCTCCAGGGAGAAAATGAAAAGTTACTATCTCAACAAGAATTGGTACCAGAACTTGAAAATACC ATAAAGAACCTTCAAGAAAAGAATGGAGTATACTTACTTAGTCTCAGTCAAAGAGATACCATGTTAAAAG AATTAGAAGGAAAGATAAATTCTCTTACTGAGGAAAAAGATGATTTTATAAATAAACTGAAAAATTCCCA TGAAGAAATGGATAATTTCCATAAGAAATGTGAAAGGGAAGAAAGATTGATTCTTGAACTTGGGAAGAAA GTAGAGCAAACAATCCAGTACAACAGTGAACTAGAACAAAAGGTAAATGAATTAACAGGAGGACTAGAGG AGACTTTAAAAGAAAAGGATCAAAATGACCAAAAACTAGAAAAACTTATGGTTCAAATGAAAGTTCTCTC TGAAGACAAAGAAGTATTGTCAGCTGAAGTGAAGTCTCTTTATGAGGAAAACAATAAACTCAGTTCAGAA AAAAAACAGTTGAGTAGGGATTTGGAGGTTTTTTTGTCTCAAAAAGAAGATGTTATCCTTAAAGAACATA TTACTCAATTAGAAAAGAAACTTCAGTTAATGGTTGAAGAGCAAGATAATTTAAATAAACTGCTTGAAAA TGAGCAAGTTCAGAAGTTATTTGTTAAAACTCAGTTGTATGGTTTTCTTAAAGAAATGGGATCAGAAGTT TCAGAAGACAGTGAAGAGAAAGATGTTGTTAATGTCCTACAGGCAGTCGGTGAATCCTTGGCAAAAATAA ATGAGGAAAAATGCAACCTGGCTTTTCAGCGTGATGAAAAAGTATTAGAGTTAGAAAAAGAGATTAAGTG CCTTCAAGAAGAGAGTGTAGTTCAGTGTGAAGAACTTAAGTCTTTATTGAGAGACTATGAGCAAGAGAAA GTTCTCTTAAGGAAAGAGTTAGAAGAAATACAGTCAGAAAAAGAGGCCCTGCAGTCTGATCTTCTAGAAA TGAAGAATGCTAATGAAAAAACAAGGCTTGAAAATCAGAATCTTTTAATTCAAGTTGAAGAAGTATCTCA AACATGTAGCAAAAGTGAAATCCATAATGAAAAAGAAAAATGTTTTATAAAGGAACATGAAAACCTAAAG CCACTACTAGAACAAAAAGAATTACGAGATAGGAGAGCAGAGTTGATACTATTAAAGGATTCCTTAGCAA AATCACCTTCTGTAAAAAATGATCCTCTGTCTTCAGTAAAAGAGTTGGAAGAAAAAATAGAAAATCTGGA AAAAGAATGCAAAGAAAAGGAGGAGAAAATAAATAAGATAAAATTAGTTGCCGTAAAGGCAAAGAAAGAA CTAGATTCCAGCAGAAAAGAGACCCAGACTGTGAAGGAAGAACTTGAATCTCTTCGATCAGAAAAGGACC AGTTATCTGCTTCCATGAGAGATCTCATTCAAGGAGCAGAAAGCTATAAGAATCTTTTATTAGAATATGA AAAGCAGTCAGAGCAACTGGATGTGGAAAAAGAACGTGCTAATAATTTTGAGCATCGTATTGAAGACCTT ACAAGACAATTAAGAAATTCGACTTTGCAGTGTGAAACAATAAATTCTGATAATGAAGATCTCCTGGCTC GTATTGAGACATTACAGTCTAATGCCAAATTATTAGAAGTACAGATTTTAGAAGTCCAGAGAGCCAAAGC AATGGTAGACAAAGAATTAGAAGCTGAAAAACTTCAGAAAGAACAGAAGATAAAGGAACATGCCACTACT GTAAATGAACTTGAAGAACTTCAGGTACAACTTCAAAAGGAAAAGAAACAGCTTCAGAAAACCATGCAAG AATTAGAGCTGGTTAAAAAGGATGCCCAACAAACCACATTGATGAATATGGAAATAGCTGATTATGAACG TTTGATGAAAGAACTAAATCAAAAGTTAACTAATAAAAACAACAAGATAGAAGATTTGGAGCAAGAAATA AAAATTCAAAAACAGAAACAAGAAACCCTACAAGAAGAAATAACTTCATTACAGTCTTCAGTACAACAAT ATGAAGAAAAAAACACCAAAATCAAGCAATTGCTTGTGAAAACCAAAAAGGAACTGGCAGATTCAAAGCA AGCAGAAACTGATCACTTAATACTTCAAGCATCTTTAAAAGGTGAGCTGGAGGCAAGCCAGCAGCAAGTA GAAGTCTATAAAATACAGCTGGCTGAAATAACATCAGAGAAGCACAAAATCCACGAGCACCTGAAAACCT CTGCGGAACAGCACCAGCGTACGCTAAGTGCATACCAGCAGAGAGTGACAGCACTACAGGAAGAGTGCCG TGCTGCCAAGGCAGAACAAGCTACTGTAACCTCTGAATTCGAGAGCTACAAAGTCCGAGTTCATAATGTT CTAAAACAACAGAAAAATAAATCTATGTCTCAGGCTGAAACTGAGGGCGCTAAACAAGAAAGGGAACATC TGGAAATGCTGATTGACCAGCTAAAAATCAAATTACAAGATAGCCAAAATAACTTACAGATTAATGTATC TGAACTTCAAACATTGCAGTCTGAACATGATACACTGCTAGAAAGGCACAACAAGATGCTGCAGGAAACT GTGTCCAAAGAGGCGGAACTCCGGGAAAAATTGTGTTCAATACAGTCAGAGAACATGATGATGAAATCTG AACATACACAGACTGTGAGTCAGCTAACATCCCAGAACGAGGTCCTTCGAAATAGCTTCCGAGATCAAGT GCGACATTTGCAGGAAGAACACAGAAAGACAGTGGAGACATTACAGCAGCAGCTCTCCAAGATGGAAGCA CAGCTCTTCCAGCTTAAGAATGAACCGACCACAAGAAGCCCAGTTTCCTCTCAACAATCTTTGAAGAACC TTCGAGAAAGGAGAAACACAGACCTCCCGCTTCTAGACATGCACACTGTAACCCGGGAAGAGGGAGAAGG CATGGAGACAACTGATACGGAGTCTGTGTCTTCCGCCAGCACATACACACAGTCTTTAGAGCAGCTGCTT AACTCTCCCGAAACTAAACTTGAGCCTCCATTATGGCATGCTGAATTTACCAAAGAAGAATTGGTTCAGA AGCTCAGTTCCACCACAAAAAGTGCAGATCACTTAAACGGCCTGCTTCGGGAAACAGAAGCAACCAATGC AATTCTTATGGAGCAAATTAAGCTTCTCAAAAGTGAAATAAGAAGATTGGAAAGGAATCAAGAGCGAGAG AAGTCTGCAGCTAACCTGGAATACTTGAAGAACGTCTTGCTGCAGTTCATTTTCTTGAAACCAGGTAGTG AAAGAGAGAGACTTCTTCCTGTTATAAATACGATGTTGCAGCTCAGCCCTGAAGAAAAGGGAAAACTTGC TGCGGTTGCTCAAGGTGAGGAAGAAAATGCTTCCCGTTCTTCTGGATGGGCATCCTATCTTCATAGTTGG TCTGGACTTCGA This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 2 / 4 GCC2 (NM_181453) Human Tagged ORF Clone – RG219795 ACGCGTACGCGGCCGCTCGAG - GFP Tag - GTTTAA Protein Sequence: >RG219795 representing NM_181453 Red=Cloning site Green=Tags(s) MEDLVQDGVASPATPGTGKSKLETLPKEDLIKFAKKQMMLIQKAKSRCTELEKEIEELRSKPVTEGTGDI IKALTERLDALLLEKAETEQQCLSLKKENIKMKQEVEDSVTKMGDAHKELEQSHINYVKEIENLKNELMA VRSKYSEDKANLQKQLEEAMNTQLELSEQLKFQNNSEDNVKKLQEEIEKIRPGFEEQILYLQKQLDATTD EKKETVTQLQNIIEANSQHYQKNINSLQEELLQLKAIHQEEVKELMCQIEASAKEHEAEINKLNELKENL VKQCEASEKNIQKKYECELENLRKATSNANQDNQICSILLQENTFVEQVVNEKVKHLEDTLKELESQHSI LKDEVTYMNNLKLKLEMDAQHIKDEFFHEREDLEFKINELLLAKEEQGCVIEKLKSELAGLNKQFCYTVE QHNREVQSLKEQHQKEISELNETFLSDSEKEKLTLMFEIQGLKEQCENLQQEKQEAILNYESLREIMEIL QTELGESAGKISQEFESMKQQQASDVHELQQKLRTAFTEKDALLETVNRLQGENEKLLSQQELVPELENT IKNLQEKNGVYLLSLSQRDTMLKELEGKINSLTEEKDDFINKLKNSHEEMDNFHKKCEREERLILELGKK VEQTIQYNSELEQKVNELTGGLEETLKEKDQNDQKLEKLMVQMKVLSEDKEVLSAEVKSLYEENNKLSSE KKQLSRDLEVFLSQKEDVILKEHITQLEKKLQLMVEEQDNLNKLLENEQVQKLFVKTQLYGFLKEMGSEV SEDSEEKDVVNVLQAVGESLAKINEEKCNLAFQRDEKVLELEKEIKCLQEESVVQCEELKSLLRDYEQEK VLLRKELEEIQSEKEALQSDLLEMKNANEKTRLENQNLLIQVEEVSQTCSKSEIHNEKEKCFIKEHENLK PLLEQKELRDRRAELILLKDSLAKSPSVKNDPLSSVKELEEKIENLEKECKEKEEKINKIKLVAVKAKKE LDSSRKETQTVKEELESLRSEKDQLSASMRDLIQGAESYKNLLLEYEKQSEQLDVEKERANNFEHRIEDL TRQLRNSTLQCETINSDNEDLLARIETLQSNAKLLEVQILEVQRAKAMVDKELEAEKLQKEQKIKEHATT VNELEELQVQLQKEKKQLQKTMQELELVKKDAQQTTLMNMEIADYERLMKELNQKLTNKNNKIEDLEQEI KIQKQKQETLQEEITSLQSSVQQYEEKNTKIKQLLVKTKKELADSKQAETDHLILQASLKGELEASQQQV EVYKIQLAEITSEKHKIHEHLKTSAEQHQRTLSAYQQRVTALQEECRAAKAEQATVTSEFESYKVRVHNV LKQQKNKSMSQAETEGAKQEREHLEMLIDQLKIKLQDSQNNLQINVSELQTLQSEHDTLLERHNKMLQET VSKEAELREKLCSIQSENMMMKSEHTQTVSQLTSQNEVLRNSFRDQVRHLQEEHRKTVETLQQQLSKMEA QLFQLKNEPTTRSPVSSQQSLKNLRERRNTDLPLLDMHTVTREEGEGMETTDTESVSSASTYTQSLEQLL NSPETKLEPPLWHAEFTKEELVQKLSSTTKSADHLNGLLRETEATNAILMEQIKLLKSEIRRLERNQERE KSAANLEYLKNVLLQFIFLKPGSERERLLPVINTMLQLSPEEKGKLAAVAQGEEENASRSSGWASYLHSW SGLR TRTRPLE - GFP Tag - V Restriction Sites: SgfI-MluI Cloning Scheme: This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 3 / 4 GCC2 (NM_181453) Human Tagged ORF Clone – RG219795 Plasmid Map: ACCN: NM_181453 ORF Size: 5052 bp OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_181453.3 RefSeq Size: 6918 bp RefSeq ORF: 5055 bp Locus ID: 9648 UniProt ID: Q8IWJ2, B3KR21 Gene Summary: The protein encoded by this gene is a peripheral membrane protein localized to the trans- Golgi network. It is sensitive to brefeldin A. This encoded protein contains a GRIP domain which is thought to be used in targeting. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2009] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 4 / 4.
Load more

Recommended publications
  • Multiple Activities of Arl1 Gtpase in the Trans-Golgi Network Chia-Jung Yu1,2 and Fang-Jen S
    © 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 1691-1699 doi:10.1242/jcs.201319 COMMENTARY Multiple activities of Arl1 GTPase in the trans-Golgi network Chia-Jung Yu1,2 and Fang-Jen S. Lee3,4,* ABSTRACT typical features of an Arf-family GTPase, including an amphipathic ADP-ribosylation factors (Arfs) and ADP-ribosylation factor-like N-terminal helix and a consensus site for N-myristoylation (Lu et al., proteins (Arls) are highly conserved small GTPases that function 2001; Price et al., 2005). In yeast, recruitment of Arl1 to the Golgi as main regulators of vesicular trafficking and cytoskeletal complex requires a second Arf-like GTPase, Arl3 (Behnia et al., reorganization. Arl1, the first identified member of the large Arl family, 2004; Setty et al., 2003). Yeast Arl3 lacks a myristoylation site and is an important regulator of Golgi complex structure and function in is, instead, N-terminally acetylated; this modification is required for organisms ranging from yeast to mammals. Together with its effectors, its recruitment to the Golgi complex by Sys1. In mammalian cells, Arl1 has been shown to be involved in several cellular processes, ADP-ribosylation-factor-related protein 1 (Arfrp1), a mammalian including endosomal trans-Golgi network and secretory trafficking, lipid ortholog of yeast Arl3, plays a pivotal role in the recruitment of Arl1 droplet and salivary granule formation, innate immunity and neuronal to the trans-Golgi network (TGN) (Behnia et al., 2004; Panic et al., development, stress tolerance, as well as the response of the unfolded 2003b; Setty et al., 2003; Zahn et al., 2006).
    [Show full text]
  • Genome Structural Variation
    Genome Structural Variation Evan Eichler Howard Hughes Medical Institute University of Washington January 18th, 2013, Comparative Genomics, Český Krumlov Disclosure: EEE was a member of the Pacific Biosciences Advisory Board (2009-2013) Genome Structural Variation Deletion Duplication Inversion Genetic Variation Types. Sequence • Single base-pair changes – point mutations • Small insertions/deletions– frameshift, microsatellite, minisatellite • Mobile elements—retroelement insertions (300bp -10 kb in size) • Large-scale genomic variation (>1 kb) – Large-scale Deletions, Inversion, translocations – Segmental Duplications • Chromosomal variation—translocations, inversions, fusions. Cytogenetics Introduction • Genome structural variation includes copy- number variation (CNV) and balanced events such as inversions and translocations—originally defined as > 1 kbp but now >50 bp • Objectives 1. Genomic architecture and disease impact. 2. Detection and characterization methods 3. Primate genome evolution Nature 455:237-41 2008 Nature 455:232-6 2008 Perspective: Segmental Duplications (SD) Definition: Continuous portion of genomic sequence represented more than once in the genome ( >90% and > 1kb in length)—a historical copy number variation Intrachromosomal Interchromosomal Distribution Interspersed Configuration Tandem Importance: Structural Variation A B C TEL A B C TEL Non Allelic Homologous Recombination GAMETES NAHR A B C A B C TEL TEL Human Disease Triplosensitive, Haploinsufficient and Imprinted Genes Calvin Bridges Alfred Sturtevant
    [Show full text]
  • The Function and Therapeutic Targeting of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Brandon Golding, Anita Luu, Robert Jones and Alicia M
    Golding et al. Molecular Cancer (2018) 17:52 https://doi.org/10.1186/s12943-018-0810-4 REVIEW Open Access The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) Brandon Golding, Anita Luu, Robert Jones and Alicia M. Viloria-Petit* Abstract Lung cancer is the leading cause of death by cancer in North America. A decade ago, genomic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase were identified in a subset of non-small cell lung carcinoma (NSCLC) patients. Soon after, crizotinib, a small molecule ATP-competitive ALK inhibitor was proven to be more effective than chemotherapy in ALK-positive NSCLC patients. Crizotinib and two other ATP-competitive ALK inhibitors, ceritinib and alectinib, are approved for use as a first-line therapy in these patients, where ALK rearrangement is currently diagnosed by immunohistochemistry and in situ hybridization. The clinical success of these three ALK inhibitors has led to the development of next-generation ALK inhibitors with even greater potency and selectivity. However, patients inevitably develop resistance to ALK inhibitors leading to tumor relapse that commonly manifests in the form of brain metastasis. Several new approaches aim to overcome the various mechanisms of resistance that develop in ALK-positive NSCLC including the knowledge-based alternate and successive use of different ALK inhibitors, as well as combined therapies targeting ALK plus alternative signaling pathways. Key issues to resolve for the optimal implementation of established and emerging treatment modalities for ALK-rearranged NSCLC therapy include the high cost of the targeted inhibitors and the potential of exacerbated toxicities with combination therapies.
    [Show full text]
  • Oracle Health Sciences Omics Data Bank Programmer’S Guide Release 3.0.2.1 E35680-12
    Oracle® Health Sciences Omics Data Bank Programmer’s Guide Release 3.0.2.1 E35680-12 March 2016 Oracle Health Sciences Omics Data Bank Programmer’s Guide Release 3.0.2.1 E35680-12 Copyright © 2013, 2016, Oracle and/or its affiliates. All rights reserved. This software and related documentation are provided under a license agreement containing restrictions on use and disclosure and are protected by intellectual property laws. Except as expressly permitted in your license agreement or allowed by law, you may not use, copy, reproduce, translate, broadcast, modify, license, transmit, distribute, exhibit, perform, publish, or display any part, in any form, or by any means. Reverse engineering, disassembly, or decompilation of this software, unless required by law for interoperability, is prohibited. The information contained herein is subject to change without notice and is not warranted to be error-free. If you find any errors, please report them to us in writing. If this is software or related documentation that is delivered to the U.S. Government or anyone licensing it on behalf of the U.S. Government, the following notice is applicable: U.S. GOVERNMENT END USERS: Oracle programs, including any operating system, integrated software, any programs installed on the hardware, and/or documentation, delivered to U.S. Government end users are "commercial computer software" pursuant to the applicable Federal Acquisition Regulation and agency-specific supplemental regulations. As such, use, duplication, disclosure, modification, and adaptation of the programs, including any operating system, integrated software, any programs installed on the hardware, and/or documentation, shall be subject to license terms and license restrictions applicable to the programs.
    [Show full text]
  • 39UTR Shortening Identifies High-Risk Cancers with Targeted Dysregulation
    OPEN 39UTR shortening identifies high-risk SUBJECT AREAS: cancers with targeted dysregulation of GENE REGULATORY NETWORKS the ceRNA network REGULATORY NETWORKS Li Li1*, Duolin Wang2*, Mengzhu Xue1*, Xianqiang Mi1, Yanchun Liang2 & Peng Wang1,3 Received 1 2 15 April 2014 Key Laboratory of Systems Biology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, College of Computer Science and Technology, Jilin University, 3School of Life Science and Technology, ShanghaiTech University. Accepted 3 June 2014 Competing endogenous RNA (ceRNA) interactions form a multilayered network that regulates gene Published expression in various biological pathways. Recent studies have demonstrated novel roles of ceRNA 23 June 2014 interactions in tumorigenesis, but the dynamics of the ceRNA network in cancer remain unexplored. Here, we examine ceRNA network dynamics in prostate cancer from the perspective of alternative cleavage and polyadenylation (APA) and reveal the principles of such changes. Analysis of exon array data revealed that both shortened and lengthened 39UTRs are abundant. Consensus clustering with APA data stratified Correspondence and cancers into groups with differing risks of biochemical relapse and revealed that a ceRNA subnetwork requests for materials enriched with cancer genes was specifically dysregulated in high-risk cancers. The novel connection between should be addressed to 39UTR shortening and ceRNA network dysregulation was supported by the unusually high number of P.W. (wangpeng@ microRNA response elements (MREs) shared by the dysregulated ceRNA interactions and the significantly sari.ac.cn) altered 39UTRs. The dysregulation followed a fundamental principle in that ceRNA interactions connecting genes that show opposite trends in expression change are preferentially dysregulated. This targeted dysregulation is responsible for the majority of the observed expression changes in genes with significant * These authors ceRNA dysregulation and represents a novel mechanism underlying aberrant oncogenic expression.
    [Show full text]
  • A SARS-Cov-2 Protein Interaction Map Reveals Targets for Drug Repurposing
    Article A SARS-CoV-2 protein interaction map reveals targets for drug repurposing https://doi.org/10.1038/s41586-020-2286-9 A list of authors and affiliations appears at the end of the paper Received: 23 March 2020 Accepted: 22 April 2020 A newly described coronavirus named severe acute respiratory syndrome Published online: 30 April 2020 coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than Check for updates 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efcacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and eforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identifed the human proteins that physically associated with each of the SARS-CoV-2 proteins using afnity-purifcation mass spectrometry, identifying 332 high-confdence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.
    [Show full text]
  • The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
    cancers Review The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis 1, 2, , 1, Stephen P. Ducray y , Karthikraj Natarajan y z, Gavin D. Garland z, 1, , 2,3, , Suzanne D. Turner * y and Gerda Egger * y 1 Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK 2 Department of Pathology, Medical University Vienna, 1090 Vienna, Austria 3 Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria * Correspondence: [email protected] (S.D.T.); [email protected] (G.E.) European Research Initiative for ALK-related malignancies; www.erialcl.net. y These authors contributed equally to this work. z Received: 7 June 2019; Accepted: 23 July 2019; Published: 30 July 2019 Abstract: Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in neuronal and gut development. Initially discovered in T cell lymphoma, ALK is frequently affected in diverse cancers by oncogenic translocations. These translocations involve different fusion partners that facilitate multimerisation and autophosphorylation of ALK, resulting in a constitutively active tyrosine kinase with oncogenic potential. ALK fusion proteins are involved in diverse cellular signalling pathways, such as Ras/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Janus protein tyrosine kinase (JAK)/STAT. Furthermore, ALK is implicated in epigenetic regulation, including DNA methylation and miRNA expression, and an interaction with nuclear proteins has been described. Through these mechanisms, ALK fusion proteins enable a transcriptional programme that drives the pathogenesis of a range of ALK-related malignancies. Keywords: ALK; ALCL; NPM-ALK; EML4-ALK; NSCLC; ALK-translocation proteins; epigenetics 1. Introduction Anaplastic lymphoma kinase (ALK) was first successfully cloned in 1994 when it was reported in the context of a fusion protein in cases of anaplastic large cell lymphoma (ALCL) [1].
    [Show full text]
  • GCC2 Is a New Biomarker for Diagnosis of Early Non-Small Cell Lung Cancer and a Potential Target to Reverse Epithelial to Mesenchymal Transition
    GCC2 is a New Biomarker for Diagnosis of Early Non-Small Cell Lung Cancer and A Potential Target to Reverse Epithelial to Mesenchymal Transition Hyesun Jeong Korea University - Seoul Campus: Korea University Byeong Hyeon Choi Korea University Guro Hospital Jik-han Jung Korea advanced institute of science and Technology Hyunku Shin Korea university JinA Park Korea university Ka-Won Kang Korea University Anam Hospital Yu Hua Quan Korea University Guro Hospital Jewon Yu Exopert incorporation Ji-Ho Park KAIST: Korea Advanced Institute of Science and Technology Yong Park Korea University Anam Hospital Yeonho Choi Korea University - Anam Campus: Korea University Hyun Koo Kim Korea University Guro Hospital Sunghoi Hong ( [email protected] ) Korea University https://orcid.org/0000-0003-4926-1044 Research Keywords: Exosomes, non-small cell lung cancer, GCC2, biomarker, therapeutic target Page 1/24 Posted Date: December 29th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-135611/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/24 Abstract Background: Nano-sized exosomes (30–150 nm) are cell membrane-encapsulated vesicles that contain nucleic acids and proteins. Specic markers detecting non-small cell lung cancer (NSCLC) cell-derived exosomes in the blood circulation remain unidentied. Here, we report a new biomarker distinguishing cancer from non-cancer exosomes that also involved in epithelial to mesenchymal transition for cancer treatment. Methods: Exosomes were isolated from plasma of patients with various pathological stages of NSCLC and NSCLC cell lines, human pulmonary alveolar epithelial cells by size exclusion chromatography and characterized by Nanoparticle Tracking Analysis and western-blotting.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, SAN DIEGO Measuring
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Measuring and Correlating Blood and Brain Gene Expression Levels: Assays, Inbred Mouse Strain Comparisons, and Applications to Human Disease Assessment A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences by Mary Elizabeth Winn Committee in charge: Professor Nicholas J Schork, Chair Professor Gene Yeo, Co-Chair Professor Eric Courchesne Professor Ron Kuczenski Professor Sanford Shattil 2011 Copyright Mary Elizabeth Winn, 2011 All rights reserved. 2 The dissertation of Mary Elizabeth Winn is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California, San Diego 2011 iii DEDICATION To my parents, Dennis E. Winn II and Ann M. Winn, to my siblings, Jessica A. Winn and Stephen J. Winn, and to all who have supported me throughout this journey. iv TABLE OF CONTENTS Signature Page iii Dedication iv Table of Contents v List of Figures viii List of Tables x Acknowledgements xiii Vita xvi Abstract of Dissertation xix Chapter 1 Introduction and Background 1 INTRODUCTION 2 Translational Genomics, Genome-wide Expression Analysis, and Biomarker Discovery 2 Neuropsychiatric Diseases, Tissue Accessibility and Blood-based Gene Expression 4 Mouse Models of Human Disease 5 Microarray Gene Expression Profiling and Globin Reduction 7 Finding and Accessible Surrogate Tissue for Neural Tissue 9 Genetic Background Effect Analysis 11 SPECIFIC AIMS 12 ENUMERATION OF CHAPTERS
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
    cancers Review Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer Wei Wu 1,2, Franziska Haderk 1,2 and Trever G. Bivona 1,2,* 1 Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA; [email protected] (W.W.); [email protected] (F.H.) 2 Department of Medicine, University of California, San Francisco, CA 94115, USA * Correspondence: [email protected]; Tel.: +1-415-885-3882 Received: 2 October 2017; Accepted: 28 November 2017; Published: 30 November 2017 Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3–7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved small molecule inhibitors targeting ALK fusion proteins, drug resistance to ALK kinase inhibitors is a common problem in clinic. Thus, there is an unmet need to deepen the current understanding of genomic characteristics of ALK rearrangements and to develop novel therapeutic strategies that can overcome ALK inhibitor resistance. In this review, we present the genomic landscape of ALK fusions in the context of co-occurring mutations with other cancer-related genes, pointing to the central role of genetic epistasis (gene-gene interactions) in ALK-driven advanced-stage lung cancer. We discuss the possibility of targeting druggable domains within ALK fusion partners in addition to available strategies inhibiting the ALK kinase domain directly. Finally, we examine the potential of targeting ALK fusion-specific neoantigens in combination with other treatments, a strategy that could open a new avenue for the improved treatment of ALK positive lung cancer patients.
    [Show full text]
  • Computational Analysis and Verification of Molecular Genetic
    Bioscience Reports (2020) 40 BSR20201401 https://doi.org/10.1042/BSR20201401 Research Article Computational analysis and verification of molecular genetic targets for glioblastoma Liang Xue*, Haibing Liu*, Yehuang Chen, Liangfeng Wei and Jingfang Hong Department of Neurosurgery, 900 Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, P.R. China Correspondence: Haibing Liu ([email protected]) Background: Glioblastoma (GBM) is the most common malignant brain tumor with a poor prognosis. The initial treatment for high-grade gliomas is surgical excision. However, even with concomitant use of radiation or chemotherapy, patients are still prone to recurrence. The specific pathogenesis of GBM is still controversial. Methods: Differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) between GBM and normal brain tissues were screened. P-value was obtained by Bayes test based on the limma package. Statistical significance was set as P-value <0.05 and |Fold change (FC)| > 0.2 (GSE90886); P-value <0.05 and |FC| > 1 (GSE116520, GSE103228). Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG), protein–protein interaction (PPI) network were performed. Hub genes were selected from miRNA target genes and DEGs. GBM and normal brain tissues were extracted to verify the expression. Results: A total of 100 DEGs were overlapped in both datasets. Analysis of pathways and process enrichment tests indicated that ion transport, positive regulation of macromolecule metabolic process, cell cycle, axon guidance were enriched in the GBM. Sixteen hub genes were identified. Hub genes ADARB1 and neuropilin 1 (NRP1) were significantly associated with overall survival (OS) and disease-free survival (DFS) (P<0.05).
    [Show full text]